Adaptive innovation, intellectual property and public interest
Related news and resources
Statement to the IHR Review Committee on amendments to the International Health Regulations
IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.
Read moreImpact of a waiver of intellectual property rights for COVID-19 therapeutics
As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.
Read more
The role of intellectual property in the biopharmaceutical sector
To better understand this resulting dichotomy, this white paper answers five key questions, with a focus on applications related to innovation in the life sciences sector and the COVID-19 pandemic.
Read more